ANEB vs. DERM, CRVS, RLYB, SPRO, CNTB, TPST, ALRN, MRNS, BYSI, and LFVN
Should you be buying Anebulo Pharmaceuticals stock or one of its competitors? The main competitors of Anebulo Pharmaceuticals include Journey Medical (DERM), Corvus Pharmaceuticals (CRVS), Rallybio (RLYB), Spero Therapeutics (SPRO), Connect Biopharma (CNTB), Tempest Therapeutics (TPST), Aileron Therapeutics (ALRN), Marinus Pharmaceuticals (MRNS), BeyondSpring (BYSI), and LifeVantage (LFVN). These companies are all part of the "pharmaceutical preparations" industry.
Anebulo Pharmaceuticals (NASDAQ:ANEB) and Journey Medical (NASDAQ:DERM) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership, earnings, community ranking and profitability.
28.4% of Anebulo Pharmaceuticals shares are owned by institutional investors. Comparatively, 7.3% of Journey Medical shares are owned by institutional investors. 85.9% of Anebulo Pharmaceuticals shares are owned by company insiders. Comparatively, 19.4% of Journey Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Anebulo Pharmaceuticals received 6 more outperform votes than Journey Medical when rated by MarketBeat users. However, 100.00% of users gave Journey Medical an outperform vote while only 87.50% of users gave Anebulo Pharmaceuticals an outperform vote.
Anebulo Pharmaceuticals has a beta of -0.98, meaning that its stock price is 198% less volatile than the S&P 500. Comparatively, Journey Medical has a beta of 0.78, meaning that its stock price is 22% less volatile than the S&P 500.
Journey Medical has higher revenue and earnings than Anebulo Pharmaceuticals. Journey Medical is trading at a lower price-to-earnings ratio than Anebulo Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Journey Medical had 1 more articles in the media than Anebulo Pharmaceuticals. MarketBeat recorded 5 mentions for Journey Medical and 4 mentions for Anebulo Pharmaceuticals. Anebulo Pharmaceuticals' average media sentiment score of 1.19 beat Journey Medical's score of 0.22 indicating that Anebulo Pharmaceuticals is being referred to more favorably in the media.
Anebulo Pharmaceuticals has a net margin of 0.00% compared to Journey Medical's net margin of -4.87%. Journey Medical's return on equity of -34.08% beat Anebulo Pharmaceuticals' return on equity.
Anebulo Pharmaceuticals currently has a consensus target price of $6.67, indicating a potential upside of 121.48%. Journey Medical has a consensus target price of $8.50, indicating a potential upside of 142.17%. Given Journey Medical's higher probable upside, analysts plainly believe Journey Medical is more favorable than Anebulo Pharmaceuticals.
Summary
Journey Medical beats Anebulo Pharmaceuticals on 9 of the 16 factors compared between the two stocks.
Get Anebulo Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ANEB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ANEB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Anebulo Pharmaceuticals Competitors List
Related Companies and Tools
